Press Releases

Jul 08, 2013

Veracyte Receives Aetna Coverage for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis

Read More

Jun 28, 2013

Veracyte Completes $28 Million Series C Financing Round With GE Ventures as a New Investor

Read More

Apr 17, 2013

Veracyte Announces That New Study Suggests The Number Of Patients At Risk For Unnecessary Thyroid Surgery Is Likely On The Rise

Read More

Apr 12, 2013

Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer

Read More

Mar 12, 2013

Veracyte Announces Results of Study Assessing Use of BRAF Mutation Testing With Its Afirma® Gene Expression Classifier

Read More

Mar 08, 2013

Veracyte Announces UnitedHealthcare Coverage Policy For the Afirma® Gene Expression Classifier

Read More

Feb 15, 2013

New Article in PLOS Currents: Evidence on Genomic Tests Supports Use of Veracyte's Afirma® Gene Expression Classifier to Resolve Ambiguous Thyroid Nodule Biopsies

Read More

Jan 07, 2013

Veracyte Announces That New Guidelines Include Molecular Testing for Indeterminate Thyroid Nodules To Reduce Unnecessary Surgeries

Read More

Oct 22, 2012

Veracyte Announces Publication of Analytical Validity Study for its Afirma® Gene Expression Classifier

Read More

Aug 29, 2012

Veracyte Receives New York State License for Afirma® Gene Expression Classifier

Read More